Using CATE values to divide the combined study cohorts with estimator information (46,394 individuals) into sub-cohorts revealed that those with a greater estimated glycemic advantage with glucagon-lile-peptide-1 receptor agonists over SGLT2 inhibitors were predominantly older and female, with lower initial HbA1c, body mass index (BMI), and estimated glomerular filtration rate (eGFR)
The guidance also highlights major hurdles, including high cost, limited supply and uneven access around the world
USE IN PATIENTS WITH HEPATIC IMPAIRMENT One clinical trial has been published assessing the safety, tolerability, and pharmacokinetics of oral semaglutide in patients with hepatic impairment
If you're considering a larger supply, it makes sense to review the label on a smaller initial order before scaling up
Cell Mol Life Sci
Dosing tiers: Sermorelin protocols run longer than CJC/Ipamorelin cycles